image
Healthcare - Medical - Instruments & Supplies - NYSE - CA
$ 16.06
0.375 %
$ 5.66 B
Market Cap
-17.84
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Mar, 2, 2025.

The intrinsic value of one BLCO stock under the worst case scenario is HIDDEN Compared to the current market price of 16.1 USD, Bausch + Lomb Corporation is HIDDEN

This DCF valuation model was last updated on Mar, 2, 2025.

The intrinsic value of one BLCO stock under the base case scenario is HIDDEN Compared to the current market price of 16.1 USD, Bausch + Lomb Corporation is HIDDEN

This DCF valuation model was last updated on Mar, 2, 2025.

The intrinsic value of one BLCO stock under the best case scenario is HIDDEN Compared to the current market price of 16.1 USD, Bausch + Lomb Corporation is HIDDEN

2. FUNDAMENTAL ANALYSIS
FINANCIALS
4.77 B REVENUE
15.15%
162 M OPERATING INCOME
24.62%
-305 M NET INCOME
-22.98%
232 M OPERATING CASH FLOW
1464.71%
-412 M INVESTING CASH FLOW
80.46%
178 M FINANCING CASH FLOW
-91.43%
1.28 B REVENUE
7.02%
87 M OPERATING INCOME
102.33%
-2 M NET INCOME
-13.33%
22 M OPERATING CASH FLOW
-85.71%
-185 M INVESTING CASH FLOW
-92.71%
146 M FINANCING CASH FLOW
830.00%
Balance Sheet Bausch + Lomb Corporation
image
Current Assets 2.79 B
Cash & Short-Term Investments 305 M
Receivables 1.03 B
Other Current Assets 1.46 B
Non-Current Assets 10.7 B
Long-Term Investments 0
PP&E 1.48 B
Other Non-Current Assets 9.2 B
Current Liabilities 1.74 B
Accounts Payable 389 M
Short-Term Debt 40 M
Other Current Liabilities 1.31 B
Non-Current Liabilities 5.19 B
Long-Term Debt 4.74 B
Other Non-Current Liabilities 443 M
EFFICIENCY
Earnings Waterfall Bausch + Lomb Corporation
image
Revenue 4.77 B
Cost Of Revenue 1.87 B
Gross Profit 2.9 B
Operating Expenses 2.76 B
Operating Income 162 M
Other Expenses 467 M
Net Income -305 M
RATIOS
60.79% GROSS MARGIN
60.79%
3.39% OPERATING MARGIN
3.39%
-6.64% NET MARGIN
-6.64%
-4.90% ROE
-4.90%
-2.35% ROA
-2.35%
1.79% ROIC
1.79%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Bausch + Lomb Corporation
image
Net Income -305 M
Depreciation & Amortization 436 M
Capital Expenditures -291 M
Stock-Based Compensation 92 M
Change in Working Capital 0
Others 19 M
Free Cash Flow -59 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Bausch + Lomb Corporation
image
Wall Street analysts predict an average 1-year price target for BLCO of $21.7 , with forecasts ranging from a low of $18 to a high of $25 .
BLCO Lowest Price Target Wall Street Target
18 USD 12.08%
BLCO Average Price Target Wall Street Target
21.7 USD 34.91%
BLCO Highest Price Target Wall Street Target
25 USD 55.67%
4. DIVIDEND ANALYSIS
5. COMPETITION
6. Ownership
Insider Ownership Bausch + Lomb Corporation
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
505 K USD 1
6-9 MONTHS
0 USD 0
9-12 MONTHS
Date Value Insider Amount Avg Price
6 months ago
Aug 05, 2024
Bought 505 K USD
SAUNDERS BRENT L
CEO and Chairman of the Board
+ 32250
15.661 USD
2 years ago
Jun 01, 2022
Sell 77.6 M USD
Bausch Health Companies Inc.
director:
- 4550357
17.055 USD
2 years ago
May 10, 2022
Sell 597 M USD
Bausch Health Companies Inc.
director:
- 35000000
17.055 USD
7. News
Bausch + Lomb Corporation (BLCO) Q4 2024 Earnings Call Transcript Bausch + Lomb Corporation (NYSE:BLCO ) Q4 2024 Results Conference Call February 19, 2025 8:00 AM ET Company Participants George Gadkowski - Vice President of Investor Relations Brent Saunders - CEO & Chairman Sam Eldessouky - Executive VP & CFO Yehia Hashad - Head of R&D and Chief Medical Officer Conference Call Participants Patrick Wood - Morgan Stanley Joanne Wuensch - Citibank Craig Bijou - Bank of America Larry Biegelsen - Wells Fargo Robbie Marcus - JPMorgan Denis Reznik - Raymond James Operator Greetings. Welcome to the Bausch + Lomb Fourth Quarter 2024 Earnings Call. seekingalpha.com - 1 week ago
Bausch + Lomb (BLCO) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates While the top- and bottom-line numbers for Bausch + Lomb (BLCO) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values. zacks.com - 1 week ago
Bausch & Lomb to shake up contact lenses with deal off the table Bausch & Lomb said this month it had explored taking the company private with a third-party buyer. No deal was reached as a consortium of private equity firms TPG and Blackstone reportedly backed out. youtube.com - 1 week ago
Bausch + Lomb (BLCO) Surpasses Q4 Earnings and Revenue Estimates Bausch + Lomb (BLCO) came out with quarterly earnings of $0.25 per share, beating the Zacks Consensus Estimate of $0.24 per share. This compares to earnings of $0.24 per share a year ago. zacks.com - 1 week ago
Unlocking Q4 Potential of Bausch + Lomb (BLCO): Exploring Wall Street Estimates for Key Metrics Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Bausch + Lomb (BLCO), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended December 2024. zacks.com - 2 weeks ago
Bausch Health Provides Update on Strategic Alternatives LAVAL, QC / ACCESS Newswire / February 6, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) (the "Company" or "Bausch Health"), a global, diversified pharmaceutical company enriching lives through a relentless drive to deliver better health outcomes, issued the following update on a potential sale of its subsidiary, Bausch + Lomb Corporation (NYSE:BLCO)(TSX:BLCO), which was disclosed in December 2024 following a regulatory request: "In the second half of 2024, Bausch Health engaged with its financial advisors to work on various liability management alternatives. At the same time, Bausch + Lomb was approached by a private equity firm with an indication of interest for a potential sale of Bausch + Lomb at a compelling valuation. accessnewswire.com - 3 weeks ago
Bausch and Lomb CEO: Right on track with our important initiatives Brent Saunders, Bausch and Lomb CEO, joins 'Money Movers' to discuss how Saunders has changed the portfolio in his time as chief executive, what the growth is like for Bausch and Lomb, and much more. youtube.com - 1 month ago
Bausch + Lomb Corporation (BLCO) Q3 2024 Earnings Call Transcript Bausch + Lomb Corporation (NYSE:BLCO ) Q3 2024 Results Conference Call October 30, 2024 8:00 AM ET Company Participants George Gadkowski - Vice President of Investor Relations and Business Insights Brenton Saunders - CEO & Chairman Osama Eldessouky - Executive VP & CFO Conference Call Participants Patrick Wood - Morgan Stanley Xuyang Li - Jefferies Matt Miksic - Barclays Doug Miehm - RBC Capital Markets Lilia-Celine Lozada - JPMorgan Operator Good morning and welcome to Bausch + Lomb's Third Quarter 2024 Earnings Call. [Operator Instructions] Please note this event is being recorded. seekingalpha.com - 4 months ago
Bausch + Lomb (BLCO) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates The headline numbers for Bausch + Lomb (BLCO) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals. zacks.com - 4 months ago
Bausch + Lomb (BLCO) Q3 Earnings and Revenues Top Estimates Bausch + Lomb (BLCO) came out with quarterly earnings of $0.17 per share, beating the Zacks Consensus Estimate of $0.16 per share. This compares to earnings of $0.22 per share a year ago. zacks.com - 4 months ago
Why Bausch + Lomb Stock Soared by Over 7% on Monday It was quite a busy and eventful day for the company. fool.com - 4 months ago
Bausch + Lomb Stock Pops as TPG, Blackstone Consider Joint Bid Bausch + Lomb Corporation (BLCO) shares popped Monday morning following reports Blackstone (BX) and TPG (TPG) are considering teaming up to buy the eyecare company. investopedia.com - 4 months ago
8. Profile Summary

Bausch + Lomb Corporation BLCO

image
COUNTRY CA
INDUSTRY Medical - Instruments & Supplies
MARKET CAP $ 5.66 B
Dividend Yield 0.00%
Description Bausch + Lomb Corporation operates as an eye health company worldwide. It operates through three segments: Vision Care/Consumer Health Care, Ophthalmic Pharmaceuticals, and Surgical. The Vision Care/Consumer Health Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products, over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions comprising eye allergies, conjunctivitis, and dry eye. The Ophthalmic Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of eye conditions, such as glaucoma, ocular hypertension, and retinal diseases; and contact lenses for therapeutic use. The Surgical segment provides tools and technologies for the treatment of cataracts, and vitreous and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices. The company was founded in 1853 and is headquartered in Vaughan, Canada.
Contact 520 Applewood Crescent, Vaughan, ON, L4K 4B4 https://www.bausch.com
IPO Date May 6, 2022
Employees 13500
Officers Mr. Jonathon L. Kellerman Chief Compliance Officer Mr. T.J. Crawford Chief Communications Officer Dr. Manisha A. Narasimhan Ph.D. Chief Corporate Development & Digital Officer Dr. Yehia Hashad M.D. Executive Vice President of Research & Development and Chief Medical officer Mr. Andrew Stewart President of Global Pharmaceuticals & International Consumer Mr. Frederick J. Munsch Senior Vice President, Controller & Chief Accounting Officer Mr. Brenton L. Saunders J.D. Chief Executive Officer & Chairman Mr. Alan Waterhouse CPFA, MBA Executive Vice President and Chief Supply Chain & Operations Officer Mr. Osama A. Eldessouky Executive Vice President & Chief Financial Officer Mr. A. Robert D. Bailey Executive Vice President & Chief Legal Officer